Bortezomib with Dexamethasone in Newly Diagnosed Patients with Primary Systemic Light Chain Amyloidosis or Multiple Myeloma-Associated AL Amyloidosis

被引：1
|
作者：
Huang, Beihui [1 ]
Li, Juan [1 ]
Liu, Junru [1 ]
Zheng, Dong [1 ]
Chen, Mei [1 ]
Zhou, Zhenhai [1 ]
Xu, Duorong [1 ]
Zou, Waiyi [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510275, Guangdong, Peoples R China
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5036.5036
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5036
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nail dystrophy as the initial sign of multiple myeloma-associated systemic amyloidosis
    Xu, Jia
    Tahan, Steven
    Jan, Farhana
    Do, Daihung
    Wu, Hong
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (06) : 543 - 545
  • [22] Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis
    Hannah A. Blair
    Drugs, 2022, 82 : 683 - 690
  • [23] Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
    Bahlis, N. J.
    Lazarus, H. M.
    BONE MARROW TRANSPLANTATION, 2006, 38 (01) : 7 - 15
  • [24] Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
    Kastritis, Efstathios
    Dialoupi, Ioanna
    Gavriatopoulou, Maria
    Roussou, Maria
    Kanellias, Nikolaos
    Fotiou, Despina
    Ntanasis-Stathopoulos, Ioannis
    Papadopoulou, Elektra
    Ziogas, Dimitrios C.
    Stamatelopoulos, Kimon
    Manios, Efstathios
    Ntalianis, Argyrios
    Eleutherakis-Papaiakovou, Evangelos
    Papanikolaou, Asimina
    Migkou, Magdalini
    Papanota, Aristea-Maria
    Gakiopoulou, Harikleia
    Psimenou, Erasmia
    Tselegkidi, Maria Irini
    Tsitsilonis, Ourania
    Kostopoulos, Ioannis
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD ADVANCES, 2019, 3 (20) : 3002 - 3009
  • [25] Myeloma-associated systemic amyloidosis presenting as digital nodules
    Miyagawa, S
    Fukumoto, T
    Tsukaguchi, N
    Hoshii, Y
    Ishihara, T
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) : 602 - 602
  • [26] A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
    Cibeira, Maria T.
    Oriol, Albert
    Lahuerta, Juan J.
    Mateos, Maria-Victoria
    de la Rubia, Javier
    Hernandez, Miguel T.
    Granell, Miquel
    Fernandez de Larrea, Carlos
    San Miguel, Jesus F.
    Blade, Joan
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) : 804 - 813
  • [27] Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
    N J Bahlis
    H M Lazarus
    Bone Marrow Transplantation, 2006, 38 : 7 - 15
  • [28] Light chain multiple myeloma with cutaneous AL amyloidosis
    Becker, Maria Rita
    Rompel, Rainer
    Plum, Joerg
    Gaiser, Timo
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2008, 6 (09): : 744 - 746
  • [29] Myeloma-associated Systemic Amyloidosis with an Extensive Cutaneous Involvement
    Aggarwal, Parul
    Aggarwal, Kamal
    Kaur, Sarabjit
    Jain, Vijay Kumar
    INDIAN JOURNAL OF DERMATOLOGY, 2017, 62 (04)
  • [30] Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
    Theodorakakou, Foteini
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
12345